Stock 2H51 OCUGEN, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Ocugen, Inc. Börse Stuttgart

Equities

2H51

US67577C1053

Real-time Estimate Tradegate
Other stock markets
 07:06:51 17/07/2024 pm IST 		5-day change 1st Jan Change
1.723 EUR -2.21% Intraday chart for Ocugen, Inc. +7.50% +220.95%
01/07 Ocugen, Inc.(NasdaqCM:OCGN) added to Russell Small Cap Completeness Index CI
01/07 Ocugen, Inc.(NasdaqCM:OCGN) added to Russell Microcap Growth Index CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Ocugen, Inc.(NasdaqCM:OCGN) added to Russell Small Cap Completeness Index
CI
Ocugen, Inc.(NasdaqCM:OCGN) added to Russell Microcap Growth Index
CI
Ocugen, Inc.(NasdaqCM:OCGN) added to Russell 2000 Index
CI
Ocugen, Inc.(NasdaqCM:OCGN) added to Russell 3000E Index
CI
Ocugen, Inc.(NasdaqCM:OCGN) added to Russell Microcap Index
CI
Ocugen, Inc.(NasdaqCM:OCGN) added to Russell 3000 Growth Index
CI
Ocugen, Inc.(NasdaqCM:OCGN) added to Russell 3000E Growth Index
CI
Ocugen, Inc.(NasdaqCM:OCGN) added to Russell 2000 Growth Index
CI
Ocugen, Inc.(NasdaqCM:OCGN) added to Russell 2000 Dynamic Index
CI
Ocugen, Inc.(NasdaqCM:OCGN) added to Russell 2500 Growth Index
CI
Ocugen, Inc.(NasdaqCM:OCGN) added to Russell Small Cap Comp Growth Index
CI
Ocugen, Inc.(NasdaqCM:OCGN) added to Russell 2500 Index
CI
Ocugen, Inc.(NasdaqCM:OCGN) added to Russell 3000 Index
CI
Kaival Brands Innovations Group (NASDAQ: KAVL) Secures $6M in Public Offering, Stock Surges Watch VTAK, OCGN, DYAI, INBS
AQ
Ocugen, Inc.(NasdaqCM:OCGN) added to S&P Biotechnology Select Industry Index
CI
Sector Update: Health Care Stocks Steady Premarket Friday
MT
Ocugen's Receives Nod to Enrol in High Dose Study of Stargardt Disease Drug Candidate
MT
Ocugen Announces Data and Safety Monitoring Board Approves Enrollment in High Dose Cohort 3 in GARDian Study for Stargardt Disease
GL
Ocugen, Inc. Announces Data and Safety Monitoring Board Approves Enrollment in High Dose Cohort 3 in GARDian Study for Stargardt Disease
CI
Ocugen, Inc. Announces First Patient Dosed in Phase 3 liMeliGhT Clinical Trial for OCU400—First Gene Therapy in Phase 3 with a Broad Retinitis Pigmentosa Indication
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. OCGN Stock
  4. 2H51 Stock
  5. News Ocugen, Inc.